Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Key Points
The transaction involved the sale of 4,375 shares at $26.12 per share, representing a total transaction value of $114,275 on Aug. 3, 2026.
The sale reduced the insider's total equity holdings by 0.46%, leaving a substantial post-transaction position valued at $24.65 million.
Ownership remains divided between ~717,000 shares held directly and ~233,000 shares held indirectly through entities including The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, Watanabe Ventures, LLC, and The Watanabe 2016 Irrevocable Trust.
The transaction was a non-discretionary execution to cover tax withholding obligations related to the vesting of restricted stock units and does not reflect a change in the insider's outlook.
- 10 stocks we like better than Arcutis Biotherapeutics ›
Todd Watanabe, president and CEO of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) sold 4,375 shares on Aug. 3, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $114,275 |
| Shares sold | 4,375 |
| Post-transaction shares (total) | 950,337 |
| Post-transaction shares (directly held) | 717,203 |
| Post-transaction shares (indirectly held) | 233,134 |
| Post-transaction value | $24.65 million |
Transaction value based on SEC Form 4 weighted average sale price ($26.12); post-transaction value based on Aug. 3, 2026, market close ($25.94).
Key questions
- What was the motivation behind this disposition of shares?
The sale was non-discretionary, executed solely to satisfy tax withholding requirements associated with the vesting of Restricted Stock Units. This type of transaction is routine and does not typically signal a shift in management's sentiment regarding the company's valuation or prospects. - How is the insider's indirect ownership structured?
The ~233,000 shares held indirectly are distributed across multiple vehicles, including The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, and The Watanabe 2016 Irrevocable Trust, as well as an entity called Watanabe Ventures, LLC. Todd Watanabe disclaims beneficial ownership of these securities except to the extent of his pecuniary interest. - What is the current scale of the insider's alignment with the company?
Despite the recent sale, the insider retains a significant interest in Arcutis, holding more than 950,000 total shares. This position was valued at $24.65 million as of the Aug. 3, 2026, market close, and the stock has delivered an 82% return over the 12 months ending on the transaction date. - Are there other share classes that impact the ownership profile?
Arcutis has not reported other share classes for this insider in the current filing. The reported holdings consist entirely of common stock, providing a clear view of the insider's direct and indirect exposure to the company's equity performance.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 8/4/26) | $26.03 |
| Market Capitalization | $3.4 billion |
| Revenue (TTM) | $415.62 million |
| Net Income (TTM) | ($2.38 million) |
Company Snapshot
- Arcutis Biotherapeutics develops and commercializes innovative topical biopharmaceutical therapies for dermatological conditions, with its flagship product ARQ-151 (roflumilast cream), approved for treating plaque psoriasis and atopic dermatitis, generating the majority of the company's revenue.
- The company operates a biopharmaceutical business model focused on the development, regulatory approval, and commercialization of proprietary dermatology therapies, leveraging its expertise in topical formulations and immunomodulatory compounds.
- Arcutis primarily serves dermatologists and their patients in the United States, targeting individuals with chronic inflammatory skin conditions, including psoriasis, atopic dermatitis, and other related dermatological disorders.
Arcutis Biotherapeutics is a specialized biopharmaceutical company with a market capitalization of $3.3 billion, operating with 354 employees and generating $415.62 million in TTM revenue. The company has established a focused pipeline of topical therapies for dermatological indications, with ARQ-151 representing its primary commercial asset.
What this transaction means for investors
President and CEO Todd Watanabe’s 4,300-share sale was executed to cover tax withholding obligations connected to the vesting of restricted stock units. It’s a good reminder for investors that sometimes company insiders make portfolio moves that don’t necessarily align with their conviction in or knowledge of the company’s future.
The biopharmaceutical company released its earnings results for the second quarter of 2026 on Aug. 5. Its leading product, roflumilast, marketed as Zoryve, grew revenue in the quarter by 59% to $129.9 million on strong demand growth, and the company received approval to expand the indication for a version of the product to treat plaque psoriasis in children down to the age of 2. It’s the seventh FDA approval in four years, the company says, an impressive track record in a competitive and difficult-to-navigate regulatory market.
The company just recently became profitable, reporting net income of $15 million in the quarter, or $0.11 per share, compared to a net loss of $15.9 million ($0.13 per share) in the year-ago period, and maintained positive operating cash flow for the quarter. Arcutis raised its full-year 2026 net product sales guidance to $525 million to $540 million. Interested investors should continue to monitor the growing indications for Zoryve, including infants, for which the FDA granted a Supplemental New Drug Application, and individuals with vitiligo, which remains in clinical testing.
Aructis stock is up nearly 90% year over year, but is down 6% year to date as of Aug. 6.
Should you buy stock in Arcutis Biotherapeutics right now?
Before you buy stock in Arcutis Biotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arcutis Biotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $396,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,300,820!*
Now, it’s worth noting Stock Advisor’s total average return is 939% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 6, 2026.
Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
